CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies

摘要: Objective: To evaluate the accuracy and clinical utility of phosphorylated tau (p-tau) for diagnosis prognosis Alzheimer’s disease (AD) mild cognitive impairment (MCI). Methods: A meta-analysis was performed 19 robust studies that compared AD with healthy individuals (n = 2300), 18 non-AD dementias (n = 1892), eight MCI subjects (n = 447) six in those who did not progress to dementia (n = 388). Results: On basis levels p-tau CSF, could be discriminated from without a sensitivity (Se) 77.6%, specificity (Sp) 87.9%, positive predictive value (PPV) 90.3% negative (NPV) 73.0%. The test rated as “good”. CSF separated other an Se 71.6% Sp 77.8% but here satisfactory poor. Regarding MCI, contributed separation 79.6% 83.9% (PPV 85.9%, NPV 76.9%). Here “satisfactory”. P-tau modestly successful predicting progression (Se 81.1%, 65.3%, PPV 63.0%, 83.0%), showing higher absence rather than conversion AD. Conclusions: is good diagnostic biomarker probable AD, prognostic less adequate separating dementias.